✦ LIBER ✦

PIN40 Cost-Effectiveness of Boceprevir-Based Treatment of Chronic Genotype 1 Hepatitis C Virus (HCV) Infection From the Perspective of the German Statutory Health Insurance (SHI)

✍ Scribed by B. Becker; J. Chhatwal; S. Ferrante; E.H. Elbasha; K.J. Krobot

Book ID: 119312058
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 62 KB
Volume: 15
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2012.08.1107

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness Analysis of Boceprevi

Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal

✍ Elbasha, Elamin H.; Chhatwal, Jagpreet; Ferrante, Shannon A.; El Khoury, Antoine 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 469 KB

PIN29 Cost Effectiveness Analysis of Add

PIN29 Cost Effectiveness Analysis of Addition of Telaprevir or Boceprevir to Standard Therapy Versus Standard Therapy Alone for the Treatment of Previously Untreated Chronic Hepatitis-C Virus Genotype 1 Infection

✍ Ramachandran, S.; Mahabaleshwarkar, R.; Yang, Y. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

Cost-effectiveness analysis of sofosbuvi

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection

✍ Saab, S.; Gordon, S. C.; Park, H.; Sulkowski, M.; Ahmed, A.; Younossi, Z. 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 580 KB

PIN50 The Clinical Efficacy and Cost-Eff

PIN50 The Clinical Efficacy and Cost-Effectiveness of Boceprevir in Combination with Pegylated Interferon- Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C Patients: A Within Trial Analysis from the Perspective of the Scottish National Health Service (NHS)

✍ E. Nikoglou; S. Humphreys; A. El khoury; S.A. Ferrante; C. O' Regan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PIN43 The Use of Futility Rules in Econo

PIN43 The Use of Futility Rules in Economic Evaluations With Direct Acting Agents (DAA) in the Treatment of Genotype 1 Hepatitis C Virus (HCV) From a Spanish Health Care Perspective

✍ E.R. D'Angelo; I. Garcia Gonzalez; M.A. Simon 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

PGI18 Cost-Effectiveness of Boceprevir i

PGI18 Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C: Submission to the National Institute for Health and Clinical Excellence (NICE)

✍ S.C. Humphreys; E.H. Elbasha; S.A. Ferrante; M. Lion; C. O'Regan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB